Lv31
400 积分 2023-06-12 加入
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer
2小时前
已完结
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
2个月前
已完结
Recent Photosensitizer Developments, Delivery Strategies and Combination-based Approaches for Photodynamic Therapy
2个月前
已完结
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
2个月前
已完结
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
4个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
4个月前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
4个月前
已完结
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
4个月前
已完结
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
4个月前
已完结
皖公网安备34019202002308
